Our dedication to advancing women in the legal profession extends beyond the firm. Axinn attorneys will be speaking at the ACI 12th Annual Summit for Women Leaders in Life Sciences Law in Boston from July 30-31. The Annual Summit is an event dedicated to fostering collaboration, networking, and professional development among more than 300 attorneys and executives from the biotech, pharmaceutical, and medical device industries. It offers an important forum to exchange insights on the latest legal developments and industry challenges.
46% of Axinn Attorneys Are Women:
58%
of Associates
34%
of Partners and Counsel
63%
of The Firm’s Leadership
71%
of the Incoming Fall Class
Notable Recognitions
Axinn Speakers at the Conference
On July 30, Rebecca will speak on “Unpacking Executive Orders 14151 and 14173: Understanding the Implications, Recent Agency Guidance, and the Latest Developments in the Courts.”
Panelists will discuss a breakdown of Executive Orders 14151 and 14173; the latest guidance from the DOJ and EEOC; updates on key court cases and legal challenges; and practical insights for in-house counsel and legal teams navigating shifting regulations.
On July 31, Denise will speak on “The Verdict Is In: Analyzing the Top 10 Court Cases Impacting the Life Sciences Industry in 2025 and Critical Takeaways for Your Practice.”
Panelists will discuss high-profile cases and decisions that are currently shaking up the life sciences industry and how the latest precedents will affect future cases.
Why Leading Life Sciences Companies Turn to Axinn
- Vast knowledge and understanding of the development, approval pathways, and monetization of life science products, allowing us to achieve a client’s business goals in the face of major obstacles
- Well-established patent litigation firm with significant trial experience in controversies involving pharmaceutical, medical device, and life science patents
- Counseling services, pre-litigation strategies, and advice on the benefits of filing IPR petitions to assist clients in the selection, development, approval, and marketing of a broad range of technologies and therapies
- Unmatched depth in the skills needed to address health care collaboration and competition. We represent companies across the health care universe, including providers, payors, suppliers and distributors, technology companies, and investors
Our Life Sciences and Biotechnology Experience
- Represented Johnson & Johnson’s Synthes in a patent infringement case involving spinal implant technology filed against Globus Medical in the District of Delaware, concluding in a complete trial victory and $16M+ jury award
- Represented Actavis in an eight-year battle over the multi-billion-dollar drug Neurontin, after remand from the Federal Circuit and after Actavis’s at-risk launch. We impeached plaintiff Pfizer’s witnesses at trial and excluded key expert testimony. The case settled on very favorable terms after two weeks of trial
- Represented Natco in a successful appeal on behalf of a generic version of Tamiflu, obtaining a reversal of the trial court’s holding that a later-issued but earlier-expiring patent cannot serve as a double-patenting reference against an earlier-issued but later-expiring patent
- Defended McKesson’s RelayHealth in an FTC investigation and litigation, as well as a treble-damages follow-on class action alleging conspiracy to monopolize. Secured an advantageous early resolution
- Defended Alvogen in multiple treble-damage class action suits alleging an industry-wide conspiracy to raise prices of generic medications through the allocation of markets
Featured Viewpoints
Featured Viewpoints
The Skinny on Infringement of Method of Treatment Claims
My Prescription Costs What?
Five Healthcare Antitrust Topics to Watch at the Upcoming Health Care Transactions Conference in Nashville
FTC Throws Down the Gauntlet on Improper Orange Book Listings
Who’s Blocking Me? Competition Law Issues With Healthcare Information Blocking
Podcast
HealthyCompetition.gov Portal Seeks Public Input on Healthcare Industry Practices
